Spinal Cord Injury Pipeline: Insights, Emerging Therapies, Key Companies, and Report Assessment 2022

DelveInsight's Spinal Cord Injury Pipeline Insight 2022 report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Spinal Cord Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Spinal Cord Injury Overview
Spinal cord injury is defined as traumatic damage to the spinal cord or nerves at the end of the spinal canal. This affects the conduction of sensory and motor signals across the site of the lesion. Spinal cord injury is a debilitating neurological condition with tremendous socioeconomic impact on affected individuals and the health care system.

Key Takeaways from the Spinal Cord Injury Pipeline Report
• The Spinal Cord Injury Pipeline report offers a rich analysis of 35+ key players and 35+ key therapies.
• Some of the major companies working to develop potential drug candidates to enhance Spinal Cord Injury includes Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
• The Spinal Cord Injury pipeline therapies in different stages of development include KP-100IT, MT 3921, AST-OPC1, ALMB0166, KAND 567, and others.

Request a sample and explore more about the report offerings @ https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Spinal Cord Injury Pathophysiology
The spinal cord (SC) has three major functions in human beings: sensibility, autonomous control, and motor control. Destructive mechanisms following SCI can have grave consequences on these functions. The pathophysiology of SCI can be divided into primary and secondary damage based on the self-destructive mechanisms following initial injury. Acute phase is characterized by ionic changes, which interrupt nerve impulses and lead to edema; the subacute phase involves a series of events including ischemia, vasospasm, thrombosis, inflammatory response, free radicals (FR) production, lipid peroxidation (LP), and the activation of autoimmune responses resulting in apoptosis. Chronic phase, all the auto destructive mechanisms generated during the acute and sub-acute phase increase and demyelination processes are triggered, alongside the formation of a glial scar, which hinders axonal regeneration.

Spinal Cord Injury Diagnosis
The aim of diagnosis is to carefully assess the extent of neurological injury, the degree of residual sensory and motor function, and to identify complications. Imaging technology is an important part of the diagnostic process of chronic spinal cord injuries. Spinal cord injuries can be detected using different types of imaging which depends on the type of underlying pathology. MRI Scans are the golden standard for imaging neurological tissues such as the spinal cord, ligaments, discs and other soft tissues. Only MRI sequences of sagittal T2 were found to be useful for prognosticative purposes.

Spinal Cord Injury Treatment
Individuals with spinal cord injuries or disorders require multidisciplinary care management to achieve optimal health outcomes. Treatments for chronic SCI focus on avoiding or improving characteristic pathophysiological mechanisms, such as glial scar formation, demyelination, and astrogliosis. Treatment strategies for acute SCI are limited to preventing further damage, therapeutic strategies for chronic SCI instead focus on promoting neuronal regeneration and treating accompanying symptoms of chronic complications. Treatment for chronic SCI can be classified into Pharmacological and non-pharmacological therapies.

Spinal Cord Injury Pipeline Assessment
The assessment part of the report embraces, in depth Spinal Cord Injury commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spinal Cord Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Spinal Cord Injury Emerging Drugs
• ES 135: Eusol Biotech
• MT-3921: Mitsubishi Tanabe Pharma Corporation

Learn more about the report offering- https://www.delveinsight.com/sample-request/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Introduction
2. Executive Summary
3. Spinal Cord Injury: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spinal Cord Injury - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. ES 135: Eusol Biotech
9. Mid Stage Products (Phase II)
10. MT-3921: Mitsubishi Tanabe Pharma Corporation
11. Early Stage Products (Phase I)
12. NVG 291: NervGen Pharma
13. Preclinical/Discovery Stage Products
14. KAND-567: Kancera
15. Inactive Products
16. Spinal Cord Injury Key Companies
17. Spinal Cord Injury Key Products
18. Spinal Cord Injury- Unmet Needs
19. Spinal Cord Injury- Market Drivers and Barriers
20. Spinal Cord Injury- Future Perspectives and Conclusion
21. Spinal Cord Injury Analyst Views
22. Appendix

Do you have any query related to the report? If yes, click here- https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About DelveInsight
DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.